glutathione S-transferase mu 5 pseudogene 1Genealiases: GST1L · GSTM1L
Q-omics provides the consensus-scored GSTM5P1 profile across patient tissues and cancer cell-line models. GSTM5P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GSTM5P1 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, GSTM5P1 RNA expression shows 8,836 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, BRCA, and TGCT as cancer lineages where GSTM5P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTM5P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTM5P1 survival associations across molecular data types. GSTM5P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTM5P1 RNA expression–survival associations across cancer types. High GSTM5P1 expression shows unfavorable associations in BLCA and BRCA, but favorable associations in UCS, ACC, PAAD and OV. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for GSTM5P1 RNA expression.
This table summarizes GSTM5P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GSTM5P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTM5P1 shows lower tumor expression in BRCA, KIRP, LUAD, KICH, HNSC and KIRC. The BRCA box plot shows higher GSTM5P1 RNA expression in normal versus tumor tissue (log2 FC = −0.126, t-test p < 0.001).
This table shows molecular features associated with GSTM5P1 in patient tissues and cancer cell lines. In patient samples, GSTM5P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
